Inhibition of Thrombin-mediated Cellular Effects by Triabin, a Highly Potent Anion-binding Exosite Thrombin Inhibitor

Summary

Triabin, a 17 kDa protein from the saliva of the assassin bug Triatoma pallidipennis is a potent thrombin inhibitor interfering with the anion-binding exosite of the enzyme. The recombinant protein, produced by the baculovirus/insect cell system, was used to study the inhibitory effect on thrombin-mediated cellular responses. The thrombin (1 nM)-stimulated aggregation of washed human platelets and the rise in cytoplasmic calcium in platelets were inhibited by triabin at nanomolar concentrations. In contrast, the rise in calcium induced by the thrombin receptor-activating peptide (10 μM) was not suppressed by triabin. In isolated porcine pulmonary arteries, preconstricted with PGF_2γ, thrombin (2 nM) elicited an endothelium-dependent relaxation which was inhibited by triabin in the same concentration range as found for the inhibition of platelet aggregation. Higher concentrations of triabin were required to diminish the contractile response of endothelium- denuded pulmonary vessels to thrombin (10 nM). In cultured bovine coronary smooth muscle cells, the mitogenic activity of thrombin (3 nM), measured by [³H]thymidine incorporation, was also suppressed by triabin. In all these assays, the inhibitory effect of triabin was dependent on the thrombin concentration used.

These studies suggest that the new anion-binding exosite thrombin inhibitor triabin is one of the most potent inhibitors of thrombin-mediated cellular effects.

• References

• 1 Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors:molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-376
• 2 Harker LA. Strategies for inhibiting the effects of thrombin. Blood Coag Fibrinol 1994; 05: S47-S58
• 3 Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Expression cloning and characterization of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Semin Thromb Hemost 1992; 18: 161-166
• 4 Obberghen-Schilling vanE, Pouyssegur J. Signaling pathways of the thrombin receptor. Thromb Haemost 1993; 70: 163-167
• 5 McNicol A, Gerrard JM. Post-receptor events associated with thrombin-induced platelet activation. Blood Coag Fibrinol 1993; 04: 975-991
• 6 Glusa E. Vascular effects of thrombin. Semin Thromb Hemost 1992; 18: 296-304
• 7 Glusa E, Bretschneider E, Paintz M. Contractile effect of thrombin in porcine pulmonary arteries and the influence of thrombin inhibitors. Naunyn-Schmiedeberg’s Arch Pharmacol 1994; 349: 101-106
• 8 Glusa E, Paintz M. Relaxant and contractile responses of porcine pulmonary arteries to a thrombin receptor activating peptide (TRAP). Naunyn-Schmiedeberg’s Arch Pharmacol 1994; 349: 431-436
• 9 Glusa E. Hirudin and platelets. Semin Thromb Hemost 1991; 17: 122-125
• 10 Markwardt F. Coagulation inhibitors from blood-sucking animals. A new line of developing antithrombotic drugs. Pharmazie 1994; 49: 313-316
• 11 Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
• 12 Noeske-Jungblut C, Haendler B, Donner P, Alagon A, Possani L, Schleuning W-D. Triabin:a highly potent exosite inhibitor of thrombin. J Biol Chem 1995; 270: 28629-28634
• 13 Petri T, Neukamm B, Isemhagen M, Ockert B, Noeske-Jungblut C. Expression of triabin, a novel highly potent inhibitor of thrombin, in Sf9 and High five insect cells using a recombinant baculovirus. In: Animal Cell Technology:From Vaccines to Genetic Medicine. Carrondo MJ. (ed). Kluwer Academic Publishers; 1997. pp 525-528
• 14 Walsmann P. Über die Reinigung von Thrombinpräparaten. Pharmazie 1968; 23: 401-402
• 15 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
• 16 Fallier-Becker P, Rupp J, Fingerle J, Betz E. Smooth muscle cells from rabbit aorta. In: Cell Culture Techniques in Heart and Vessel Research. Piper HM. (ed). Springer, Berlin, Heidelberg, New York: 1990. pp 247-270
• 17 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1987; 162: 156-159
• 18 Friedrich T, Kröger B, Bialojan S, Lemaire HG, Hoffken HW, Reuschen-bach P, Otte M, Dodt J. A Kazal-type inhibitor with thrombin specificity from Rhodnius prolixus . J Biol Chem 1993; 268: 16216-16222
• 19 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112-118
• 20 Zingali RB, Jandrot-Perrus M, Guillin MC, Bon C. Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom:characterization and mechanism of thrombin inhibition. Biochemistry 1993; 32: 10794-10802
• 21 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406
• 22 Jandrot-Perrus M, Huisse MG, Krstenansky JL, Bezeaud A, Guillin MC. Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets. Thromb Haemost 1991; 66: 300-305
• 23 Kanthou C, Dennehy U, Kakkar VV, Benzakour O. Structural domains of thrombin involved in the induction of mitogenesis in cultured human vascular smooth muscle cells. Blood Coagul Fibrinol 1995; 06: 634-642
• 24 Blackhart BD, Cuenco G, Toda T, Scarborough RM, Wolf DL, Ramakrishnan V. The anion-binding exosite is critical for the high affinity binding of thrombin to the human thrombin receptor. Growth Factors 1994; 11: 17-28